(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

LIPAC ONCOLOGY

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: CombinedOffice: United States

Quick snapshot

LIPAC ONCOLOGY

ST13

US500000087614578

Class

42

Filing

87614578

Registration

5501156

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

32

Latest update

04/30/2025

Trademark type

Combined

Nice classes

42

Filing date

09/19/2017

Registration date

06/26/2018

Expiration date

-

Complete case details

Structured fields from the responsible authority and the official record.

Status date

01/29/2025

Last transaction

04/30/2025

Responsible office

United States Patent and Trademark Office

Status code

702

Official register

Principal Register

First use anywhere

11/01/2016

First use in commerce

11/01/2016

Drawing code

3

Owner type

03

Owner location

Menlo Park, CA

Examiner

BULLOFF, TOBY

Current location

Historical data usage

Mark description

The mark consists of Geometric figure comprised of circles and ovals clustered to create a partial circle swirl design with the words "LIPAC ONCOLOGY" directly to the right of the design.

Holders and representatives

Holders

LIPAC ONCOLOGY, INC.
Lipac Oncology LLC
Lipac Oncology LLC

Representatives

Kristin S. Cornuelle ORRICK, HERRINGTON & SUTCLIFFE LLP

Technical classification

Nice Classes

Class 42

Vienna Codes

No Vienna codes available.

Goods and services

Class 42

Pharmaceutical drug development services; pharmaceutical products development; pharmaceutical research and development; pharmaceutical research services

Publications

History of USPTO decisions and trademark events.

32 publications found

NURC

NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED

04/29/2025

ERRR

ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED

01/30/2025

NA85

NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED

01/29/2025

C15A

REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.

01/29/2025

A7OK

AMENDMENT UNDER SECTION 7 - PROCESSED

01/29/2025

ES7R

TEAS SECTION 7 REQUEST RECEIVED

12/27/2024

PR23

POST REGISTRATION ACTION MAILED - SEC. 8 & 15

11/21/2024

APRE

CASE ASSIGNED TO POST REGISTRATION PARALEGAL

11/21/2024

E815

TEAS SECTION 8 & 15 RECEIVED

06/07/2024

REM1

COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED

06/26/2023

ASGN

AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP

06/23/2022

CHAN

APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED

03/01/2022

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

03/01/2022

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

03/01/2022

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

03/01/2022

COAR

TEAS CHANGE OF OWNER ADDRESS RECEIVED

03/01/2022

R.PR

REGISTERED-PRINCIPAL REGISTER

06/26/2018

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

04/10/2018

PUBO

PUBLISHED FOR OPPOSITION

04/10/2018

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

03/21/2018

ALIE

ASSIGNED TO LIE

03/08/2018

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

03/02/2018

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

03/01/2018

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

02/28/2018

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

02/28/2018

GPRN

NOTIFICATION OF PRIORITY ACTION E-MAILED

01/03/2018

GPRA

PRIORITY ACTION E-MAILED

01/03/2018

CPRA

PRIORITY ACTION WRITTEN

01/03/2018

DOCK

ASSIGNED TO EXAMINER

12/22/2017

MDSC

NOTICE OF DESIGN SEARCH CODE E-MAILED

09/26/2017

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

09/25/2017

NWAP

NEW APPLICATION ENTERED

09/22/2017

Continuous trademark protection

Get notified about every new filing that threatens LIPAC ONCOLOGY or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.